guanfacine and Schizophrenia studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

Excerpt	Relevance	Reference
"Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate."	6.70	Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001)
"Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate."	2.70	Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001)
"Guanfacine, which is an alpha-2 agonist with a higher affinity for the 2A, compared with 2B or 2C, subtypes, also blocked the ability of PCP to increase dopamine efflux in the prefrontal cortex."	1.35	Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype. ( Elsworth, JD; Jentsch, JD; Roth, RH; Sanchez, D, 2008)

Research

Studies (4)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Jentsch, JD	1
Sanchez, D	1
Elsworth, JD	1
Roth, RH	1
Mehta, MA	1
Friedman, JI	2
Stewart, DG	1
Gorman, JM	1
Adler, DN	1
Temporini, HD	1
Kemether, E	1
Harvey, PD	1
White, L	1
Parrella, M	1
Davis, KL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum[NCT02524899]	Phase 2	45 participants (Actual)	Interventional	2014-01-31	Completed
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885]		16 participants (Actual)	Interventional	2008-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Middle Frontal Gyrus

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.17
Placebo	-0.094

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Superior Frontal Gyrus

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.1
Placebo	0.052